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Cisplatin is a chemotherapy agent frequently used to 
treat different types of neoplasia. Ototoxicity is one of the 
side-effects which cause significant morbidity and limits its 
use. This study aimed at assessing the role of apoptosis in 
cisplatin-induced ototoxicity. Design: experimental study. 
Materials and Methods: male Wistar rats were treated with 
intraperitoneal cisplatin, in the doses of 24 and 16 mg/kg. 
The animals were assessed by means of distortion product 
evoked otoacoustic emissions (DPEOAE) or brainstem evoked 
auditory potentials (BEAP) in the third (D3) and fourth (D4) 
days after drug infusion onset. Following that, their cochleas 
were removed for immunohistochemical studies of apoptosis 
- TUNEL method. Results: the group treated with 24 mg/kg 
showed a significant reduction in DPEOAE amplitude, and 
such fact was not seen with the 16 mg/kg. Both doses caused 
an increase in BEAP electrophysiological threshold in D3 
and D4. Apoptosis was the injury mechanism responsible for 
the cisplatin-induced ototoxicity - 16 mg/kg dose, when the 
animals were assessed on D3. Conclusion: apoptosis may 
be involved in the cisplatin-induced ototoxicity, depending 
on the dose and time of injury assessment.
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INTRODUCTION
The cochlea is the fundamental sensorineural struc-
ture in the peripheral auditory process of the acoustic 
message. It is made up by a series of complex epithelial 
structures, with sensorial and support cells located on the 
basilar membrane. Its damage, almost always irreversible, 
may have dire consequences for the affected individual, 
which may have his communication capacity compromi-
sed, with severe social impairment. On the other hand, 
despite the ototoxic potential of some antineoplastic drugs, 
cisplatin among them, they must not be disregarded as a 
treatment alternative for patients with malignant neoplasia. 
Thus the importance of establishing exactly the mecha-
nisms through which the ototoxic effects of such drugs, 
in order to search for strategies to reduce such toxicity, 
without compromising its therapeutic effect1.
Cisplatin (cisdiaminodicloroplatinum - CCDP) is a 
frequently used chemotherapeutic agent in the treatment of 
many types of neoplasias, especially of the head and neck2. 
The antineoplastic action mechanism is associated to the 
selective and persistent inhibition of the deoxyribonucleic 
acid synthesis (DNA)3. Its side effects include ototoxicity, 
kidney toxicity, medullar suppression and gastrointestinal 
disorders4. These types of toxicity can impact treatment 
- as it reduces the chemotherapy dosage, frequency and 
duration for many patients5.
Cisplatin-induced ototoxicity was first described by 
Rossof et al., in 1972, and it has been broadly studied since 
then6. Its incidence seems to vary between 4 and 50%7-9, 
although alterations in the high frequency audiometry may 
be seen in almost all the cases10.
This type of lesion seems to result from free-radicals-
induced damage to many tissues11-14. It has been shown 
that oxygen reactive species are generated in the cochlea 
after exposure to cisplatin15 and that such oxidative stress 
can cause cochlear cell death by apoptosis secondary to 
the activation of caspase-316.
Apoptosis is an active form of cell death which 
occurs during normal development, as well as when cells 
are exposed to certain types of attacking agents such as 
ischemia/hypoxia, radiation or toxin17 and this lesion 
mechanism seems to be the pathophysiological basis of 
cisplatin-induced ototoxicity.
Inner ear cell apoptosis can be triggered by the 
formation of complexes between cisplatin and the DNA 
of the damaged cell, preventing the progression of the 
cell cycle18-20. Another pathway proposed for cisplatin-
induced ototoxicity in animal models establishes that the 
drug-induced oxidative stress would trigger a cascade of 
intracellular reactions which ultimately lead to apoptosis13.
Liu et al.21 and Cheng et al.22, through experiments 
with cultures of organ of Corti cells from 3 day-old Wistar 
rats showed the role of apoptosis as mechanism of cell 
lesion by cisplatin. Watanabe et al.23 identified fragmented 
DNA in the spiral ganglion and stria vascularis of guinea 
pigs submitted to treatment with 10 mg/kg of cisplatin. Ho-
wever, this finding was not seen in the organ of Corti hair 
cells. In the study by Alam et al.24 with Mongolian rodents, 
the identification of apoptotic cells after the administration 
of CCDP 20 mg/kg, happened in all cochlear structures, 
including the inner and outer hair cells, support cells, 
spiral ganglion cells, stria vascularis and spiral ligament. 
Devarajan et al.18 also showed evidence in culture of organ 
of Corti cells from rats, that CDDP promotes apoptosis 
in lower concentrations and that higher doses can lead 
directly to cell necrosis, and these two mechanisms can 
represent a continuum. Wang et al.25 showed that the 10 
mg/kg dose of cisplatin was capable of inducing apoptosis 
to the cochleas of guinea pigs, especially in the outer hair 
cells, the inner hair cells and stria vascularis. They also 
reported that through transmission electron microscopy 
they noticed other lesion mechanisms such as autolysis and 
necrosis can be involved in cisplatin-induced ototoxicity.
The apoptosis of cochlear hair cells is dependent on 
the expression of pro-apoptotic proteins such as p5312, 
caspases21,22,25, calpain26, Bax and Bid18, c-jun NH2-terminal 
kinase (JNK)22 and antiapoptotic such as BCL-218,24. There-
fore, to reduce inner ear cell apoptosis without inhibiting 
the antitumoral effect of CDCP can be a valid strategy 
to reduce the ototoxic effects of this chemotherapeutic 
agent27. This study aimed at assessing the role of apoptosis 
in the cisplatin-induced cochlear lesion in rats.
MATERIALS AND METHODS
For our study we used male Wistar rats with wei-
ghts varying between 200 and 348g, kept in cages with 
free access to food and water, in natural sleep and wake 
cycles, and handled according to the standards advocated 
by the Brazilian College of Experimentation with Animals 
(COBEA), found at the website: www.cobea.org.br. The 
project was submitted to the approval of the Ethics in Re-
search with Animals Committee (CEPA), and was approved 
under protocol # 28/05.
The animals were divided in 8 groups according to 
dose, means of cisplatin administration, type and time of 
functional assessment (n= number of rats).
Group 1 (n=11): Rats treated with cisplatin at the 
dose of 8 mg/kg/day during 3 consecutive days (total of 
24 mg/kg) and assessed before treatment (D0) and three 
days (D3) after its onset by distortion product evoked 
otoacoustic emissions (DPOAE).
Group 2 (n=6): Rats treated with saline solution at 
the dose of 8 ml/kg/day during 3 consecutive days (total 
of 24 ml/kg) and assessed before treatment (D0) and three 
days (D3) after its onset by distortion product otoacoustic 
emissions (DPOAE).
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Group 3 (n=8): Rats treated with cisplatin at the 
dose of 8 mg/kg/day during 3 consecutive days (total of 
24 mg/kg) and assessed before treatment (D0) and four 
days (D4) after its onset by distortion product otoacoustic 
emissions (DPOAE).
Group 4 (n=6): Rats treated with saline solution at 
the dose of 8 ml/kg/day during 3 consecutive days (total 
of 24 ml/kg) and assessed before treatment (D0) and on 
the 4th day after its onset (D4) by distortion product oto-
acoustic emissions (DPOAE).
Group 5 (n=12): Rats treated with cisplatin in a 
single dose of 16 mg/kg/day and assessed before treat-
ment (D0) and three days (D3) after its onset by distortion 
product otoacoustic emissions (DPOAE).
Group 6 (n=5): Rats treated with saline solution in 
a single dose of 16 ml/kg/day and assessed before treat-
ment (D0) and three days (D3) after its onset by means of 
distortion product otoacoustic emissions (DPOAE).
Group 7 (n=7): Rats treated with cisplatin in a single 
dose of 16 mg/kg/day and assessed before treatment (D0) 
and four days (D4) after its onset by means of distortion 
product otoacoustic emissions (DPOAE).
Group 8 (n=6): Rats treated with saline solution in 
a single dose of 16 ml/kg/day and assessed before treat-
ment (D0) and four days (D4) after its onset by means of 
distortion product otoacoustic emissions (DPOAE).
In a parallel study, similar animals were divided 
into four groups in an attempt to assess its pre and post 
treatment thresholds and hearing by means of brainstem 
evoked auditory potentials (BEAP), thus being:
Group 9 (n=11): Rats treated with cisplatin in the 
dose of 8 mg/kg/day for 3 consecutive days (total of 24 
mg/kg) and evaluated before treatment (D0), three (D3) 
and four days (D4) after its onset by brainstem evoked 
auditory potential (BEAP).
Group 10 (n=7): Rats treated with saline solution in 
the dose of 8 ml/kg/day for 3 consecutive days (total of 
24 ml/kg) and assessed before treatment (D0), three (D3) 
and four days (D4) after its onset by brainstem evoked 
auditory potentials (BEAP).
Group 11 (n=12): Rats treated with cisplatin in a 
single dose of 16 mg/kg/day and assesses before treat-
ment (D0), three (D3) and four days (D4) after its onset 
by means of brainstem evoked auditory potentials (BEAP).
Group 12 (n=8): Rats treated with saline solution 
in a single dose of 16 ml/kg/day and assessed before tre-
atment (D0), three (D3) and four days (D4) after its onset 
by brainstem evoked auditory potentials (BEAP).
The Wistar rats were submitted to deep anesthesia 
by ketamine 50 mg/kg associated with xylazine 10 mg/kg. 
A prior otoscopy was carried out eliminating the animals 
with signs of middle and outer ear disorders. Those with 
normal otoscopy were submitted to distortion product 
evoked otoacoustic emissions (DPEOAE), immediately 
before the administration of the drugs. In the 8 mg/kg 
cisplatin for 3 consecutive days or 8 ml/kg saline solution 
for 3 consecutive day’s groups, the drugs were injected 
in the peritoneum immediately after the conclusion of the 
first auditory assessment. In the two subsequent days, after 
a new weighing of the rats, 8 mg/kg cisplatin or 8 ml/kg 
saline solution were administered again, in order to result 
in a final respective dose of 24 mg/kg and 24 ml/kg. Twen-
ty four (D3) or 48h (D4) after the last administration, the 
rats were anesthetized again, a new otoscopy was carried 
out in order to rule out those with external or middle ear 
disorders during the period of drug administration, and 
were submitted to a new auditory evaluation by DPEOAE. 
In the groups in which cisplatin was injected by intrape-
ritoneal via in the single dose of 16 mg/kg and 16 ml/kg 
saline, we used a Kd Scientific series 100 infusion pump in 
order to fix the infusion time to 30min. When necessary, a 
new dose of anesthetics was injected. Auditory evaluation 
was also carried out on the third (D3) or fourth (D4) days 
after drug administration.
Immediately after the last auditory evaluation by 
DPEOAE, we removed the right temporal bone, after 
slaughtering, by guillotine beheading. The cochlea was 
dissected by the immunohistochemical technique as des-
cribed in subsequent items.
In the four last groups (9 to 12), the animals were 
submitted to the same procedures of anesthesia, otoscopy 
and injection of drugs aforementioned, without, however, 
removing temporal bones for immunohistochemical pur-
poses. The auditory assessment was carried out by means 
of BEAP (Brainstem Evoked Auditory Potential), and the 
same group of animals was submitted to the exam imme-
diately before and on the third and fourth days after the 
administration of the drugs. 
The distortion product evoked otoacoustic emission 
tests (DPEOAE) were carried out by means of a MADSEN 
Capella - GN Otometrics otoacoustic emissions device, 
in a silent environment. The rats were anesthetized and 
in their right external auditory meatus we inserted the 
device’s probe, using probes which are used with newborn 
babies. The stimulus encompassed 2 pure tones (F1 and 
F2) which F1/F2 frequency ratio was equal to 1.22. The 
stimulus intensity was fixed to 70 dB SPL. We analyzed a 
total of 1000 inputs. The resulting otoacoustic emissions 
were assessed in the frequencies of 3, 4, 6 and 8 kHz. We 
considered the presence of DPEOAE for a signal/noise 
(S/N) ratio of, at least 6 dB SPL, according to the technical 
specifications of the device used.
In order to perform the brainstem evoked auditory 
potential test (BEAP) we used the Interacoustic EP 25 
device in a silent room. With the animals anesthetized, 
platinum subdermal electrodes were placed on the vertex 
(positive), right retroauricular region (negative) and nasal 
tip (ground). ER-3A insertion earphones were coupled to 
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the probe used to do auditory assessment of newborns 
and were introduced in the right external auditory meatus 
of the rats. The stimuli employed were rarefaction clicks, 
sounded at a rate of 15 per second, with a total of 700 
clicks during a 15msec analysis time. The passing band 
used was from 0 to 3,000 Hz. The stimuli started at 80 
dB HL and were progressively reduced until complete 
wave disappearance. For the electrophysiological auditory 
threshold, we considered the lowest stimulus intensity in 
which we could notice the wave II.
In the immunohistochemistry for apoptosis by the 
TUNEL (TdT-mediated dUTP nick end-labeling) method, 
four 4mm slices of the cochlea were made, along the 
modiulus, and were prepared in slides covered with L-
polylysine. For this technique we used the ApopTagR S 
7100 (Chemicon International) kit. The histological cross-
sections had the paraffin removed by xylol and were 
rehydrated with decreasing concentrations of alcohol 
(absolute, 95% and 70%). Following that, they were flu-
shed in phosphate buffer solution (PBS) and incubated at 
room temperature with proteinase K for 15min in order 
to promote antigenic recovery. After flushed with distilled 
water, the material was treated with 3% hydrogen pero-
xide volume per volume in PBS during 5min, in order to 
block endogenous peroxidase. A new flushing with PBS 
was carried out and afterwards the histology cross-sections 
were incubated with Equilibration Buffer for 10s and imme-
diately after with the TdT (desoxynucleotidil transferase) 
enzyme, associated with the nucleotides marked with 
digoxygenin (reaction buffer) which would bind to the 
free fragmented DNA hydroxyls from the apoptotic cells. 
The negative control was not treated with the enzyme. 
The material remained in the oven at 37oC for 1h and the 
reaction was concluded with the stop solution. Flushing 
with PBS, following that the addition of antidigoxygenin 
tandem solution and incubation at room temperature for 30 
minutes. Another PBS flushing and added to DAB (diami-
nobenzidin), the peroxidase substrate, then incubated for 
3 to 6min, in order to develop the reaction color. Flushing 
with distilled water, immersion in 100% N-butanol and 
xylol and, after that, the slides were setup with EntelanR.
In order to quantify the color intensity of the struc-
tures, we made microphotographies of the basal turn with 
a 100x magnification through the Leica DFC 320 digital 
capture system. Using the Histomorphometric Analysis 
System software (SAHM 1.0), an area corresponding to the 
middle ramp of the Corti spiral organ, spiral ganglion, stria 
vascularis and spiral ligament was selected and assessed 
the dyed area over non-dyed area ratio (pixels/pixels). 
The SAHM 1.0 software selects a pre-defined color one 
wishes to evaluate and quantifies the area occupied by 
such color (Fig. 1).
In order to make the graphs and do the statistical 
analysis we used the GraphPad Prism 4.00.255 software. 
We assessed the normal sample distribution through the 
Komogorov-Smirnov test. Results were expressed as mean 
± the mean standard error (MED ± EPM), for the conti-
nuous data, and as median (Md) and minimum (Min) and 
maximum (Max) values for the ordinal data. The minimum 
significance accepted was 5%. The experimental procedu-
res were compared using the following tests:
T-Student test in order to compare the distortion 
product otoacoustic emission mean values in each fre-
quency before and after treatment and to compare the 
dyed area fraction in relation to the non-dyed area by 
immunohistochemistry following the TUNEL method in 
each group treated with cisplatin and its control.
ANOVA variance analysis with significance between 
the groups established by the Tukey test in order to com-
pare the mean values of the electrophysiological thresholds 
of the animals obtained by means of the brainstem evoked 
auditory potential on the first (D0), fourth (D3) and fifth 
(D4) days of assessment.
RESULTS
Functional hearing assessment by Distortion Product 
Evoked Otoacoustic Emissions (DPEOAE)
We found a significant reduction in the DPEOAE 
amplitude within the frequencies tested (3, 4, 6 and 8 kHz) 
between D0 and D3 for the group that received cisplatin 
at the dose of 24 mg/kg (Group 1). Such reduction was 
not found in the control group. (Figs. 2 A, B, C and D).
Group 3 showed a high animal mortality on D4 
after the procedure. Of the eight animals which received 
cisplatin in the cumulative dose of 24 mg/kg, only 3 remai-
ned alive for the DPEOAE test on D4. Of these, 2 had no 
DPEOAE, proven by a signal/noise ratio difference lower 
Figure 1. Histomorphometric analysis, after TUNEL immunohistoche-
mistry technique, of an animal treated with 16mg/kg of cisplatin, which 
had its cochlea removed on D3. The brown color indicates cell death. 
A. Color seen before selection and quantification of the dyed area. B. 
After selection of the area to be analyzed by the SAMH 1.0 software, 
isolating the brown points.
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than 6 dB SPL, in the frequencies of 3 and 4 kHz. One 
animal also did not show DPEOAE in the 6 kHz frequency. 
In the 8 kHz frequency we noticed a significant reduction 
in DPEOAE amplitude between D0 and D4 (Fig. 3).
With the dose of 16 mg/kg of cisplatin, it was not 
possible to identify a statistically significant reduction in 
DPEOAE mean amplitude values between D0 and D3 and 
between D0 and D4, in all the frequencies studied (p > 
0.05) ( Figs. 4 A, B, C and D and 5 A,B,C and D).
Figure 2. Graph showing the DPEAOAE amplitude values as mean ± 
mean standard error on days D0 and D3, for groups 1 and 2. The aste-
risk represents statistical significance. CDDP = cisplatin; C = control. 
Graph A: frequency of 3 kHz (T test T: * p = 0.0095 - D3 x D0 CDDP). 
Graph B: 4 kHz frequency (T -Test: * p = 0.0073 - D3 x D0 CDDP). Graph 
C: 6 kHz frequency (T Test: * p = 0.0284 - D3 x D0 CDDP). Graph D: 
8 kHz frequency (T test: * p = 0.0338 - D3 x D0 CDDP).
Figure 3. Graph of the DPEAOAE amplitude values expressed as 
mean ± mean standard error on days D0 and D4, of groups 3 and 4 
in the 8 kHz frequency. The asterisk represents statistical significance. 
CDDP = cisplatin; C = control. T- Test: * p = 0.0459 (D4 x D0 CDDP).
Figure 4. Graph of the DPEAOAE amplitude values expressed as 
mean ± mean standard error in the averages of days D0 and D3, for 
groups 5 and 6. CDDP = cisplatin; C = control. There was no statistical 
significance in any of the groups (T test: p > 0.05).
Figure 5. Graph of DPEAOAE amplitude values expressed as mean ± 
mean standard error in the averages of days D0 and D4, of groups 7 and 
8. CDDP = cisplatin; C = control. There was no statistical significance 
in any of the groups (T test: p > 0.05).
750
Brazilian Journal of otorhinolaryngology 75 (5) SeptemBer/octoBer 2009
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
Functional hearing assessment by brainstem evoked au-
ditory potential (BEAP)
There was a significant increase in the mean elec-
trophysiological threshold in the animals injected with 
24 mg/kg cisplatin on D3 and D4 when compared to 
D0. We did not notice a statistically significant difference 
of these thresholds between D3 and D4. In the control 
group there was no elevation of the electrophysiological 
thresholds (Fig. 6).
DISCUSSION
Cisplatin is one of the most broadly used and effec-
tive chemotherapeutic agents against epithelial malignant 
tumors, including testicle, ovary, gallbladder, lung head 
and neck19. Some of its side effects, such as nausea, vo-
mits, renal dysfunction, can be controlled with the use of 
serotonin receptor antagonists and hydration28. Neverthe-
Figure 6. Graph showing the mean electrophysiologic thresholds 
of groups 9 and 10 in D0, D3 and D4, expressed as mean ± mean 
standard error (MED ± EPM). The asterisk represents a statistically 
significant difference. CDDP = cisplatin; C = control. ANOVA - Tukey: 
* p < 0.01 (D3 x D0 CDDP); * p < 0.001 (D4 x D0 CDDP).
We noticed a significant increase in the mean elec-
trophysiological threshold of the animals injected 16 mg/
kg cisplatin on D3 when compared to D0. We did not 
notice statistically significant differences of these thresholds 
between D3 and D4. In the control group there was also 
no elevation in the electrophysiological thresholds (Fig. 7)
Apoptosis in Cisplatin-Induced Ototoxicity
Cells were marked by the TUNEL method in the 
areas of the membranous labyrinth (inner and outer hair 
cells, stria vascularis, spiral ligament, spiral limbos, spiral 
ganglion) for both doses and in the control groups. Com-
paring the color intensity between each treated group 
and its control with the SAHM 1.0 software we noticed a 
significantly larger number of marked cells by the TUNEL 
method on the cochleas of the animals treated with 16 
mg/kg cisplatin, which had their temporal bones removed 
on D3. There was no significant difference between the 
other groups and their controls (Fig. 8).
Figure 7. Graph showing the mean electrophysiologic thresholds 
of groups 11 and 12 in D0, D3 and D4, expressed as mean ± mean 
standard error (MED ± EPM). The asterisk represents a statistically 
significant difference. CDDP = cisplatin; C = control. ANOVA - Tukey: 
* p < 0.05 (D3 x D0 CDDP).
Figure 8. Graph showing the mean fraction ± mean standard error 
(MED ± EPM) of the colored area (TUNEL positive) in the cochlea basal 
turn of the animals from the different groups. The asterisk represents 
statistical significance. T-test: * p = 0.0013 (Group 5 - CDDP 16 D3 
DPEAOAE x Group 6 - control).
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less, ototoxicity remains as one of the side effects which 
cause significant morbidity and which frequent curbs its 
use29. For this reason, we need to develop experimental 
models in order to better understand the mechanisms 
involved in cisplatin-induced toxicity and many feasible 
ways to minimize it.
Functional hearing evaluation of rats in the experi-
ment was first carried out through the DPEOAE - distortion 
product evoked otoacoustic emissions, since it is the only 
method available to date with which the study could be 
carried out. During the experiments, we acquired a BEAP 
device, which made possible to carry out a functional as-
sessment of hearing in rats by brainstem evoked auditory 
potential. Thus, it was not possible to submit the same 
group of animals to both methods of functional evaluation.
In the present study, it was only the 24 mg/kg dose 
that was capable of triggering a cisplatin-induced ototoxi-
city measurable by DPEOAE in all the frequencies studied.
When the functional assessment was carried out 
through the brainstem evoked auditory potential (BEAP), 
we noticed an increase in the electrophysiological 
threshold in the two doses employed.
Some studies suggest that cisplatin can cause cell 
damage because it interacts with DNA chain nucleophilic 
sites, triggering mechanisms which result in apoptosis19. 
This effect, which is beneficial in terms of the neoplasia 
treatment, is the very basis for understanding the ototo-
xicity of this drug20.
Another mechanism proposed to explain this 
cisplatin-induced adverse effect is through the oxidative 
stress which would cause irreversible cell damage and 
apoptosis11,13,17,18,25,26,30.
In the present study we were able to use the im-
munohistochemistry TUNEL method (ApopTagR) to detect 
DNA fragmented chains and establish that the cochleas of 
rats treated with 16 mg/kg of cisplatin and which had their 
temporal bones removed 3 days later were significantly 
marked when compared to the controls. All the structures 
of the membranous labyrinth were marked, including the 
inner and outer hair cells, support cells; stria vascularis, 
spiral ganglion, spiral ligament, spiral limbos, and these 
results were similar to those reported by Alam et al.24 in 
Mongolian rodents. Despite the 24 mg/kg dose and the 
animals assessed on D3 and D4, as well as the dose of 16 
mg/kg assessed on D4, the cells marked by TUNEL were 
also in evidence, their color intensity was not different from 
the respective controls. These findings lead us to believe 
that the lower dose, for a shorter assessment time was 
capable of triggering cell apoptosis, while higher doses 
or a longer evaluation time were associated with other 
mechanisms of cell death such as autolysis or necrosis. 
Studies carried out by Liu et al.21 and Cheng et al.31 in 
cultures of P-3 Wistar P-3 rat cells also showed a TUNEL 
marking pattern with the use of cisplatin. Devarajan et 
al.18, used the TUNEL method (ApopTagR) also in cultu-
res of organ of Corti cells, proposed that lower cisplatin 
doses led to cell death by apoptosis, while larger doses 
led straight to necrosis, and these two mechanisms of cell 
death are a continuum. A study with guinea pigs in inner 
ear surface preparation showed the DNA fragmentation 
TUNEL pattern in outer hair cells and stria vascularis and 
less DNA fragmentation in inner hair cells with the use of 
3 mg/kg cisplatin during five consecutive days32. These 
authors have also identified other mechanisms of cell 
damage, other than apoptosis, through the use of trans-
mission electron microscopy. Some cells had vacuolated 
cytoplasm and intact cytoplasmatic membrane, suggesting 
autolysis. Others showed necrosis signs such as cell debris 
and cytoplasmic membrane disintegration.
The cochlear cell color in the control group is 
probably related to the cell lesion triggered by the very 
method used to remove this organ through beheading of 
the animal. 
With this, apoptosis is part of the cell damage me-
chanisms in cisplatin-induced ototoxicity, depending on 
the dose and time of assessment used. Moreover, cells in 
apoptosis, if its natural evolution is followed, could have 
necrosis as final outcome.
CONCLUSION
The 16 mg/kg cisplatin dose with assessment on 
the third day after its administration had apoptosis as 
mechanism of cell damage.
For higher doses of cisplatin (24 mg/kg) or assess-
ment on the fourth day after its administration, other lesion 
mechanisms, different from apoptosis, may be involved.
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